Broliden K, Abreu E R, Arneborn M, Böttiger M
Department of Clinical Virology, Swedish Institute for Infectious Disease Control, Stockholm, Sweden.
Vaccine. 1998 Jan-Feb;16(2-3):323-7. doi: 10.1016/s0264-410x(97)88332-6.
Sweden was the first country in the world to introduce a two-dose programme of vaccination against measles, mumps and rubella with a combined vaccine (MMR). It was commenced in 1982 and the vaccination was carried out at the ages of 18 months and 12 years. In 1992-93 the first age-group vaccinated at 18 months reached the age of 12 and accordingly received a second dose of MMR. A total of 382 children participated in the present study. Sero-immunity against mumps was studied by testing neutralizing antibodies using serial dilutions inoculated into cell cultures before and after the 12-year vaccination. Of the 229 children earlier vaccinated (group A), 27% lacked demonstrable antibodies before the booster. Of those without documented vaccination records (group B), 56% were seronegative before vaccination. After vaccination, 93% of group A and 86% of group B were seropositive (titre > or = 2). In the seronegative children, whether vaccinated earlier or not, the seroconversion was ca 75%. Previously unvaccinated children positive before vaccination and thus likely to be naturally immune had a higher mean-titre both before and after vaccination than the seropositive children earlier vaccinated. So far, the two-dose programme has proceeded as expected.
瑞典是世界上首个推行针对麻疹、腮腺炎和风疹的两剂联合疫苗(MMR)接种计划的国家。该计划于1982年启动,接种在18个月和12岁时进行。1992 - 1993年,首批在18个月时接种疫苗的年龄组满12岁,因此接受了第二剂MMR疫苗。共有382名儿童参与了本研究。通过在12岁接种疫苗前后对接种于细胞培养物中的系列稀释液进行中和抗体检测,研究了针对腮腺炎的血清免疫情况。在229名早期接种过疫苗的儿童(A组)中,27%在加强免疫前缺乏可检测到的抗体。在那些没有接种记录的儿童(B组)中,56%在接种前血清学呈阴性。接种疫苗后,A组93%和B组86%血清学呈阳性(滴度≥2)。在血清学阴性的儿童中,无论是否早期接种过疫苗,血清转化率约为75%。之前未接种过疫苗但接种前呈阳性因而可能自然免疫的儿童,接种前后的平均滴度均高于早期接种过疫苗的血清学阳性儿童。到目前为止,两剂接种计划进展顺利。